Eberhard Karls Universität Tübingen

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial (2022) Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, et al. Journal article AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas (2022) Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, et al. Journal article Synaptotagmin-13 orchestrates pancreatic endocrine cell egression and islet morphogenesis (2022) Bakhti M, Bastidas-Ponce A, Tritschler S, Czarnecki O, Tarquis-Medina M, Nedvedova E, Scheibner K, et al. Journal article Automated imaging-based abdominal organ segmentation and quality control in 20,000 participants of the UK Biobank and German National Cohort Studies (2022) Kart T, Fischer M, Winzeck S, Glocker B, Bai W, Buelow R, Emmel C, et al. Journal article Human ultrarare genetic disorders of sulfur metabolism demonstrate redundancies in H2S homeostasis (2022) Kožich V, Schwahn BC, Sokolová J, Křížková M, Ditroi T, Krijt J, Khalil Y, et al. Journal article TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome (2022) Perez-Rivas LG, Simon J, Albani A, Tang S, Roeber S, Assie G, Deutschbein T, et al. Journal article Genotyping-by-sequencing-based identification of Arabidopsis pattern recognition receptor RLP32 recognizing proteobacterial translation initiation factor IF1 (2022) Fan L, Fröhlich K, Melzer E, Pruitt RN, Albert I, Zhang L, Joe A, et al. Journal article Ingold, Tim. Correspondences. viii, 230 pp., bibliogr. Cambridge: Polity, 2020. £15.99 (paper)Taussig, Michael. Mastery of non‐mastery in the age of meltdown. 192 pp., illus., bibliogr. Chicago: Univ. Press, 2020. £20.00 (paper) (2022) Rivera Andía JJ Other publication type Human-machine-communication: introduction to the special issue (2022) Etzrodt K, Gentzel P, Utz S, Engesser S Journal article Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution